Statement 9: The second-line treatment recommendations for patients with adenocarcinoma, large-cell carcinoma, and NSCLC (ECOG PS 0-1 and PS 2) are pembrolizumab/carboplatin or cisplatin/pemetrexed (category 1) and carboplatin/pemetrexed, respectively, and for patients with SCC (PS 0-1 and PS 2) are pembrolizumab/carboplatin/paclitaxel or pembrolizumab/carboplatin/albumin-bound paclitaxel (category 1) and carboplatin/albumin-bound paclitaxel/gemcitabine/paclitaxel, respectively. This evidence concerns the gene ALB and adenocarcinoma.